Anhui Rousidousi Pharmaceutical Technology

Anhui Rousidousi Pharmaceutical Technology is a Chinese biotechnology company focused on the research and development of innovative small molecule therapeutics for metabolic diseases. The company specializes in the discovery of multi-agonist treatments targeting the GLP-1, GIP, and glucagon receptors to address conditions such as type 2 diabetes and obesity. By leveraging its expertise in medicinal chemistry, Anhui Rousidousi aims to develop next-generation oral and injectable metabolic regulators with improved efficacy and safety profiles. The firm operates primarily within the high-growth metabolic health sector in China, positioning itself as an emerging player in the competitive incretin-based therapy landscape.